Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  McKesson Corporation    MCK

MCKESSON CORPORATION

(MCK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

McKesson: Fiscal 4Q Earnings Snapshot

share with twitter share with LinkedIn share with facebook
05/20/2020 | 07:33am EDT

IRVING, Texas (AP) _ McKesson Corp. (MCK) on Wednesday reported fiscal fourth-quarter net income of $1.02 billion, after reporting a loss in the same period a year earlier.

The Irving, Texas-based company said it had profit of $5.85 per share. Earnings, adjusted for one-time gains and costs, came to $4.27 per share.

The results topped Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of $4.10 per share.

The prescription drug distributor posted revenue of $58.54 billion in the period, also topping Street forecasts. Five analysts surveyed by Zacks expected $55.42 billion.

For the year, the company reported profit of $900 million, or $4.95 per share. Revenue was reported as $231.05 billion.

McKesson expects full-year earnings in the range of $13.95 to $14.75 per share.

McKesson shares have increased almost 5% since the beginning of the year, while the Standard & Poor's 500 index has declined 9.5%. The stock has risen 14% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MCK at https://www.zacks.com/ap/MCK

Automated Insights, source Associated Press News

share with twitter share with LinkedIn share with facebook
Latest news on MCKESSON CORPORATION
07/06MCKESSON CORPORATION : to Announce First Quarter Fiscal 2021 Results on August 3..
BU
07/01MCKESSON : Changes Business-Unit Structure
DJ
07/01MCKESSON CORP : Regulation FD Disclosure, Financial Statements and Exhibits (for..
AQ
07/01MCKESSON : Realigns Organizational Structure to Better Serve Customers and Patie..
BU
06/30KARYOPHARM THERAPEUTICS : XPOVIO, FDA Approved for Treatment of Relapsed or Refr..
AQ
06/29MCKESSON : XPOVIO (selinexor), FDA Approved for Treatment of Relapsed or Refract..
PU
06/19MCKESSON : Partners with Walmart to Deliver nearly 10 million Critical Medical G..
PU
06/05MCKESSON : Appoints Tom Rodgers to Executive Vice President and Chief Strategy a..
AQ
06/04MCKESSON : Appoints Tom Rodgers to Executive Vice President & Chief Strategy and..
BU
06/03ELI LILLY AND : RETEVMO, FDA-Approved for Treatment of RET-driven Lung and Thyro..
AQ
More news
Financials (USD)
Sales 2021 236 B - -
Net income 2021 1 870 M - -
Net Debt 2021 2 045 M - -
P/E ratio 2021 12,4x
Yield 2021 1,20%
Capitalization 23 186 M 23 186 M -
EV / Sales 2020
EV / Sales 2021 0,11x
Nbr of Employees 70 000
Free-Float 59,5%
Chart MCKESSON CORPORATION
Duration : Period :
McKesson Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MCKESSON CORPORATION
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 170,59 $
Last Close Price 143,02 $
Spread / Highest target 35,6%
Spread / Average Target 19,3%
Spread / Lowest Target 2,78%
EPS Revisions
Managers
NameTitle
Brian Scott Tyler Chief Executive Officer & Director
Edward A. Mueller Chairman
Britt Vitalone Chief Financial Officer & Executive Vice President
Nancy Flores EVP, Chief Technology & Information Officer
M. Christine Jacobs Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MCKESSON CORPORATION3.40%23 186
WALGREENS BOOTS ALLIANCE, INC.-33.84%34 765
CARDINAL HEALTH, INC.-3.36%14 412
WELCIA HOLDINGS CO., LTD.26.62%8 609
SINOPHARM GROUP CO., LTD.-30.69%7 935
HUADONG MEDICINE CO., LTD18.05%7 194